Overview

Efficacy and Safety APT-1011 in Adolescent Subjects With Eosinophilic Esophagitis (EoE) - A Sub-Study of the FLUTE-2 Trial

Status:
Recruiting

Trial end date:
2022-05-12

Target enrollment:

Participant gender:

Summary

This is a randomized, double-blind, placebo-controlled study of APT-1011, followed by an open-label extension (OLE) in adolescents (≥12 to <18 years) with EoE.

Phase:

Phase 3

Details

Lead Sponsor:

Ellodi Pharmaceuticals, LP

Treatments:

Fluticasone
Xhance